人用聯合疫苗市場按產品類型、年齡層、聯合類型、通路和地區分類

預計到 2026 年，人類結合疫苗市場價值將達到 110 億美元，到 2033 年將達到 201 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 9%。

由於在兒童免疫和老年預防保健領域的應用不斷擴展，人源結合疫苗市場正經歷顯著成長。此外，生物製藥研究的拓展、mRNA多價技術的突破以及複雜製劑監管標準的加強，預計將在預測期內推動市場成長。抗原是疫苗的基本結構成分。結合疫苗檢測是製藥、生物分析和臨床產業常用的研發技術。人源結合疫苗只需單次注射即可提供多種病原體的定性和定量保護，有助於實現精準免疫並提高患者依從性。

人類結合疫苗產業正經歷創新時期，這得益於許多先進分析技術和精密遞送系統的應用，以及公共衛生、旅遊醫學、生物技術和臨床診斷等各領域對特定生化分析的高需求。這些發展正在透過擴大人類結合疫苗的產能、提高穩定性和安全性以及提升生產自動化程度變革時期市場格局。

市場動態

受製藥和生技產業對高效免疫和多價預防的高需求驅動，人源結合疫苗市場正經歷強勁成長。抗原和佐劑在疫苗研發、品管和免疫反應檢驗中發揮關鍵作用。準確測定抗原和佐劑的含量並了解其協同效應至關重要。隨著製藥業將重點放在六價疫苗和基於mRNA的多價平台等複雜生物製藥上，深入研究抗原干擾的細節將有助於確保這些複雜藥物的有效性、安全性和穩定性。

人源結合疫苗在臨床診斷和公共衛生計畫中的日益普及是推動這一市場趨勢的主要因素。在臨床診斷中，將多種抗原結合到單次注射中，對於保護和監測易感人群免受白喉、百日咳和乙型肝炎等感染疾病至關重要。新技術提高了疫苗的穩定性和有效性，使醫生能夠利用即時流行病學數據制定個人化的疫苗接種方案。

此外，全球感染疾病率的上升顯著加速了對人用結合疫苗的需求，因為這些產品在感染疾病的預防和控制中發揮著至關重要的作用。包括流感、呼吸道合胞病毒（RSV）和新冠肺炎（COVID-19）在內的傳染病通常需要精確的多價疫苗分析，以監測群體免疫並指導治療性介入。

mRNA技術在人類結合疫苗中的應用標誌著分析和保護能力的重大轉折點。新一代平台能夠以卓越的特異性和靈敏度同時遞送多種抗原。這些系統採用先進的脂質奈米顆粒（LNP）標靶化技術，即使在複雜的全球衛生環境下，也能以最少的物流設置實現快速生產和精準標靶化。

本次調查的主要特點

• 本報告對人類結合疫苗市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）內的市場規模（十億美元）和復合年成長率（%）。
• 該報告還重點介紹了各個細分市場的潛在商機，並概述了該市場具有吸引力的投資提案矩陣。
• 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
• 根據以下參數對人類結合疫苗市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
• 本報告的研究結果將使負責人和企業經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 人類結合疫苗市場報告涵蓋了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過各種用於分析人類結合疫苗市場的策略矩陣輕鬆做出決策。

目錄

第1章 研究目標與前提條件

• 調查目的
• 先決條件
• 簡稱

第2章 市場範圍

• 報告概述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監理及趨勢分析

• 市場動態
  • 促進要素
  • 抑制因素
  • 市場機遇
• 影響分析
• 近期產品發布
• 流行病學
• 合併、收購和合作
• 法規環境
• 重大進展
• PEST分析
• 夥伴關係情景
• 品牌和價格分析
• 經銷商狀態
• 波特分析
• 技術進步
• 重大進展
• 市場趨勢
• 前景
• 按銷售額排名的主要企業

4. 2026-2033年全球人用結合疫苗市場（依產品類型分類）

• 去活化疫苗
• 減毒活病毒疫苗

5. 2026-2033年全球人用結合疫苗市場（依年齡層分類）

• 兒童
• 成人

6. 2026-2033年全球人用聯合疫苗市場（以聯合類型分類）

• DTaP/IPV/B型肝炎疫苗
• DTaP/Hib/IPV
• MMR II
• 乙型肝炎/Hib
• 其他

7. 2026-2033年全球人用結合疫苗市場（依通路分類）

• 醫院藥房
• 零售藥房
• 網路藥房

8. 2026-2033年全球人用結合疫苗市場（按地區分類）

• 北美洲
  • 介紹
  • 按產品類型分類的市場規模、預測及年成長率（2026-2033年）
  • 市場規模及預測、年成長率（按年齡層別分類）
  • 按組合類型分類的市場規模和預測，以及年成長率
  • 市場規模及預測、年成長率（依通路分類）
  • 市場規模及預測、年增速（依國家/地區分類）
    • 美國
    • 加拿大
• 拉丁美洲
  • 介紹
  • 按產品類型分類的市場規模、預測及年成長率（2026-2033年）
  • 市場規模及預測、年成長率（按年齡層別分類）
  • 按組合類型分類的市場規模和預測，以及年成長率
  • 市場規模及預測、年成長率（依通路分類）
  • 市場規模及預測、年增速（依國家/地區分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲國家
• 歐洲
  • 介紹
  • 按產品類型分類的市場規模、預測及年成長率（2026-2033年）
  • 市場規模及預測、年成長率（按年齡層別分類）
  • 按組合類型分類的市場規模和預測，以及年成長率
  • 市場規模及預測、年成長率（依通路分類）
  • 市場規模及預測、年增速（依國家/地區分類）
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 比荷盧經濟聯盟
    • 丹麥
    • 挪威
    • 瑞典
    • 其他歐洲
• 亞太地區
  • 介紹
  • 按產品類型分類的市場規模、預測及年成長率（2026-2033年）
  • 市場規模及預測、年成長率（按年齡層別分類）
  • 按組合類型分類的市場規模和預測，以及年成長率
  • 市場規模及預測、年成長率（依通路分類）
  • 市場規模及預測、年增速（依國家/地區分類）
    • 中國
    • 台灣
    • 印度
    • 日本
    • 印尼
    • 馬來西亞
    • 菲律賓
    • 新加坡
    • 澳洲
    • 韓國
    • 亞太其他地區
• 中東和非洲
  • 介紹
  • 按產品類型分類的市場規模、預測及年成長率（2026-2033年）
  • 市場規模及預測、年成長率（按年齡層別分類）
  • 按組合類型分類的市場規模和預測，以及年成長率
  • 市場規模及預測、年成長率（依通路分類）
  • 市場規模及預測、年增速（依國家/地區分類）
    • 巴林
    • 科威特
    • 阿曼
    • 卡達
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 北非
    • 中非
    • 其他中東國家

第9章 競爭情勢

• Sanofi
• Pfizer Inc.
• Cadila Healthcare Ltd.
• GlaxoSmithKline plc, CSL Ltd.
• Mitsubishi Tanabe Pharma Corp.
• Daiichi Sankyo Company Limited
• Merck &Co.
• Mass Biologics
• Meiji Holdings Co. Ltd.
• Serum Institute of India
• Moderna
• AstraZeneca
• Influvac
• Biological
• PaxVax Corporation
• Emergent BioSolutions Inc.
• CNBG
• Takeda Pharmaceutical Co. Ltd.
• NPS MedicineWise

第10章各節

• 調查方法
• 關於本公司

Human Combination Vaccines Market is estimated to be valued at USD 11 Bn in 2026 and is expected to reach USD 20.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9% from 2026 to 2033.

The human combination vaccines market is advancing significantly with rising applications in pediatric immunization and geriatric preventative care. Moreover, expanding biopharmaceutical research, breakthroughs in mRNA multivalent technology, and tightening regulatory standards for complex formulations are expected to drive market growth over the forecast period. Antigens are the basic structural components of vaccines. Combination vaccine analysis is a commonly used development technique in pharmaceutical, bioanalytical, and clinical industries. Human combination vaccines are utilized for qualitative as well as quantitative protection against multiple pathogens in a single injection, which aids in accurate immunization and improved patient compliance.

The human combination vaccines industry is having a revolutionary period bolstered by a number of advancing analytical factors and the adoption of sophisticated delivery systems, along with high demand for particular biochemical analysis in different sectors, including public health, travel medicine, biotechnology, and clinical diagnostics. These developments have expanded the capabilities of human combination vaccines and enhanced their stability and safety profiles, as well as manufacturing automation, marking a transformative phase in the market.

Market Dynamics

The human combination vaccines market is experiencing robust growth fueled by the high demand for streamlined immunization and multivalent prevention within pharmaceutical and biotechnology industries. Antigens and adjuvants play a crucial role in vaccine development, quality control, and checking how immunological responses are working. It is essential to measure them accurately and understand their synergistic effects. As the pharmaceutical industry focuses more on complex biologic solutions like hexavalent shots and mRNA-based multivalent platforms, studying the details of antigenic interference helps ensure these complex drugs are effective, safe, and stable.

The expanding utilization of human combination vaccines in clinical diagnostics and public health initiatives is significantly contributing to the evolving dynamics of the human combination vaccines market. In clinical diagnostics, these formulations play a major role in protecting and monitoring vulnerable populations against infectious diseases like diphtheria, pertussis, and hepatitis B by consolidating multiple antigens into a single injection dose. The novel technology has made these vaccines more stable and effective, allowing doctors to create personalized immunization plans using real-time epidemiological data.

In addition, the rising incidence of infectious diseases worldwide is majorly speeding up the demand for human combination vaccines, as these products play a critical role in the prevention and management of such conditions. Communicable diseases, including influenza, RSV and COVID-19 usually require precise multivalent profiling to monitor population-wide immunity and guide therapeutic interventions.

The application of mRNA technology in human combination vaccines represents a significant shift in analytical and preventative capabilities. Next-generation platforms now allow for the simultaneous delivery of multiple antigens with remarkable specificity and sensitivity. These systems utilize advanced lipid nanoparticle (LNP) targeting, allowing for precise targeting as well as rapid manufacturing even in complex global health landscapes with minimal logistical preparation.

Key Features of the Study

• This report provides in-depth analysis of the human combination vaccines market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the human combination vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi, Pfizer Inc., Cadila Healthcare Ltd., GlaxoSmithKline plc, CSL Ltd., Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Company, Limited, Merck & Co., Crunchbase Inc., Mass Biologics, Meiji Holdings Co. Ltd., Serum Institute of India, Moderna, AstraZeneca, Influvac, Biological, PaxVax Corporation, Emergent BioSolutions Inc., CNBG, Takeda Pharmaceutical Co. Ltd., and NPS MedicineWise
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The human combination vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the human combination vaccines market

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2026 - 2033)
  • Inactivated vaccine
  • Live attenuated vaccine
• Age Group Insights (Revenue, USD Bn, 2026 - 2033)
  • Children
  • Adults
• Combination Type Insights (Revenue, USD Bn, 2026 - 2033)
  • DTaP/IPV/Hep B
  • DTaP/Hib/IPV
  • MMR II
  • Hep B-Hib
  • Others
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Russia
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • Sanofi
  • Pfizer Inc.
  • Cadila Healthcare Ltd.
  • GlaxoSmithKline plc
  • CSL Ltd.
  • Mitsubishi Tanabe Pharma Corp.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Merck & Co.,
  • Crunchbase Inc.
  • Mass Biologics
  • Meiji Holdings Co. Ltd
  • Serum Institute of India Moderna
  • Astrazeneca
  • Influvac
  • Biological
  • PaxVax Corporation
  • Emergent BioSolutions Inc
  • CNBG
  • Takeda Pharmaceutical Co. Ltd.
  • NPS MedicineWise

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaboration
• Regulatory Scenario
• Key Developments
• PEST Analysis
• Partnership Scenario
• Brand and Pricing Analysis
• Distributors Landscape
• Porters Analysis
• Technological Advancements
• Key Developments
• Market Trend
• Future Prospective
• Top Market Players by Revenue

4. Human Combination Vaccines Market By Product Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Inactivated vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Live attenuated vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

5. Human Combination Vaccines Market By Age Group, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

6. Human Combination Vaccines Market By Combination Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• DTaP/IPV/Hep B
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• DTaP/Hib/IPV
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• MMR II
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Hep B-Hib
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

7. Human Combination Vaccines Market By Distribution Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Retailer Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

8. Human Combination Vaccines Market By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, en2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Benelux
    • Denmark
    • Norway
    • Sweden
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • China
    • Taiwan
    • India
    • Japan
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • Bahrain
    • Kuwait
    • Oman
    • Qatar
    • Saudi Arabia
    • UAE
    • Israel
    • South Africa
    • North Africa
    • Central Africa
    • Rest of the Middle East

9. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cadila Healthcare Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GlaxoSmithKline plc, CSL Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mitsubishi Tanabe Pharma Corp.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Daiichi Sankyo Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mass Biologics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Meiji Holdings Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Serum Institute of India
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Moderna
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Influvac
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biological
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PaxVax Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Emergent BioSolutions Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CNBG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Takeda Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• NPS MedicineWise
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us